Part IV of Feiba product licence application. Provides a summary of all clinical trials carried out using Feiba Immuno. Amongst the side effects it states that in 9 cases the transmission of hepatitis as a result of FEIBA treatment could not be excluded. In some of these cases it is impossible to ascertain with absolute certainty whether the transmission of viral hepatitis was caused by FEIBA or another blood product given simultaneously. Tests were carried out from 1974 to 1980.